Improving corneal transplant success by enhancing healing and reducing inflammation
Targeting the multicellular process of corneal regeneration and vascularization to enhance outcome of cornea transplantation
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11093410
This study is looking at ways to help people who need corneal transplants, especially those with tough conditions like inflammation, by using a special protein to improve healing and reduce the chances of rejection, so patients can have better results after their surgery.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11093410 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the success rates of corneal transplants, particularly in patients with high-risk conditions such as inflammation and vascularization. The approach involves boosting the regenerative capacity of the cornea and limbus by targeting specific proteins that play a role in tissue repair and inflammation. By studying the effects of MG53, a protein involved in corneal health, the research aims to mitigate rejection rates and enhance healing processes in transplant recipients. Patients may benefit from improved outcomes and reduced complications following corneal surgery.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals undergoing corneal transplantation, especially those with high-risk factors like inflammation or vascularization.
Not a fit: Patients who do not require corneal transplantation or have stable corneal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to higher success rates for corneal transplants and better long-term vision for patients.
How similar studies have performed: Previous research has shown promising results in enhancing tissue repair and reducing inflammation using similar approaches, indicating potential for success in this area.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MA, JIANJIE — UNIVERSITY OF VIRGINIA
- Study coordinator: MA, JIANJIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.